NCT00780169View on ClinicalTrials.gov

Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

May 31, 2011

Study Completion Date

December 31, 2012

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

sorafenib + FOLFIRI

"escalating doses of sorafenib and irinotecan~* sorafenib starting dose 400 mg/day~* irinotecan starting dose 80 mg/m2 on day 1"

Trial Locations (1)

K1H 8L6

The Ottawa Hospital Cancer Centre, Ottawa

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Ottawa Hospital Research Institute

OTHER